NATCO Pharma Limited’s Board of Directors met on February 12, 2026, to approve the Unaudited Financial Results for Q3 FY2026. The Board declared a third interim dividend of ₹1.50 per share for FY 2025-26, setting the record date for February 18, 2026. Additionally, several key managerial personnel, including the Chairman & Managing Director, were re-appointed for one year effective April 1, 2026. The appointment of a new CFO was also confirmed.
Q3 FY2026 Financial Performance Highlights
The Board of Directors of NATCO Pharma Limited considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. The accompanying financial statements provide detailed metrics compared across previous periods.
Consolidated Financial Snapshot (Q3 FY2026)
According to the press release, NATCO recorded a consolidated total revenue of INR 705.4 Crore for the quarter ended December 31, 2025, up from INR 651.1 crore in the corresponding period last year (Q3 FY2025). The consolidated EBITDA stood at INR 216.8 Crore, resulting in margins of 30.7%. The net profit for the quarter on a consolidated basis was INR 151.3 Crore.
Segmental Revenue Split (INR Crore)
The segmental analysis highlights shifts in revenue contribution:
- Active Pharmaceutical Ingredients (API): ₹64.3 Crore in Q3FY26 (vs. ₹66.6 Crore in Q3FY25).
- Domestic Formulations: ₹119.8 Crore in Q3FY26 (vs. ₹96.1 Crore in Q3FY25).
- Formulations export (Incl. profit share and subs): ₹421.4 Crore in Q3FY26.
The Total Consolidated Revenue for Q3FY26 reached ₹705.4 Crore.
Interim Dividend Declaration
The Board has declared the third interim dividend of ₹1.50/- (Rupees one and fifty paise only) (75%) per equity share of ₹2/- face value for the financial year 2025-26. The record date for eligibility of payment is fixed as Wednesday, February 18, 2026, with dividend payments commencing from February 26, 2026.
Key Board Decisions on Management Changes
Following recommendations from the Nomination and Remuneration Committee, the Board re-appointed several key directors for a period of one year, effective April 1, 2026:
- Sri Venkaiah Chowdary Nannapaneni: Re-appointed as Chairman & Managing Director.
- Sri Rajeev Nannapaneni: Re-appointed as Vice Chairman & Chief Executive Officer.
- Sri Potluri Sivaramakrishna Prasad: Re-appointed as Director and Executive Vice President (Corporate Engineering Services).
- Dr. Donthineni Linga Rao: Re-appointed as Director & President (Tech. Affairs), including remuneration approval.
The company confirmed that all re-appointed directors are not debarred from holding office. The shareholders’ approval for these re-appointments will be sought via Postal Ballot.
Changes in Financial Leadership
The Board noted the superannuation of Mr. S. V. V. N. Appa Rao, Chief Financial Officer, effective the close of business hours on February 12, 2026. Subsequently, the appointment of Mr. Amit Parekh, Executive Vice President – Finance & Accounts, as the new Chief Financial Officer was approved, effective February 13, 2026.
Corporate Structure Updates
The Board also approved the following corporate structure changes:
- Appointment of Mr. Kalakuntla Srinivas Rao as Executive Vice President – Pharma Division, effective February 12, 2026.
- Approval to incorporate a wholly owned subsidiary in Chile with an investment up to US$ 3,00,000, to be named NATCO Pharma Chile SPA.
- The re-constitution of the Environmental, Social and Governance (ESG) Committee and Risk Management Committee, effective February 13, 2026.
Associate Company Update
The results include the performance of Adcock Ingram Holdings Limited (Associate). For the first half of its financial year ending December 31, 2025, Adcock reported a profit after tax of INR 198 Crore on revenues of INR 2,464 Crore. NATCO’s share of profit pick-up for the period from November 10 to December 31, 2025, amounted to INR 29.65 Crore, which, after a one-time amortization of INR 18.75 Crore, resulted in an associate profit reflection of INR 10.90 Crore in NATCO’s financials.
Source: BSE
